tradingkey.logo

Bausch + Lomb Corp

BLCO
15.745USD
+0.745+4.97%
Close 11/05, 16:00ETQuotes delayed by 15 min
5.58BMarket Cap
LossP/E TTM

Bausch + Lomb Corp

15.745
+0.745+4.97%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Bausch + Lomb Corp

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bausch + Lomb Corp's Score

Industry at a Glance

Industry Ranking
89 / 210
Overall Ranking
196 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 14 analysts
Hold
Current Rating
16.231
Target Price
+6.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bausch + Lomb Corp Highlights

StrengthsRisks
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 27.15% year-on-year.
Fairly Valued
The company’s latest PE is -17.39, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 39.05M shares, decreasing 38.44% quarter-over-quarter.
Held by Larry Robbins
Star Investor Larry Robbins holds 1.55M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.85, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.28B, representing a year-over-year increase of 7.11%, while its net profit experienced a year-over-year increase of 800.00%.

Score

Industry at a Glance

Previous score
6.85
Change
0

Financials

4.66

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

5.97

Operational Efficiency

8.74

Growth Potential

7.63

Shareholder Returns

7.26

Bausch + Lomb Corp's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.63, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -17.39, which is -6442.62% below the recent high of 1103.27 and -282.50% above the recent low of -66.53.

Score

Industry at a Glance

Previous score
8.63
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 89/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 6.71, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Bausch + Lomb Corp is 17.00, with a high of 19.00 and a low of 13.00.

Score

Industry at a Glance

Previous score
6.71
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 14 analysts
Hold
Current Rating
16.231
Target Price
+8.21%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Bausch + Lomb Corp
BLCO
14
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Dexcom Inc
DXCM
30
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 7.25, which is higher than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 16.08 and the support level at 13.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
8.61
Change
-1.36

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
-0.022
Neutral
RSI(14)
57.904
Neutral
STOCH(KDJ)(9,3,3)
56.337
Buy
ATR(14)
0.523
High Vlolatility
CCI(14)
45.039
Neutral
Williams %R
19.286
Overbought
TRIX(12,20)
0.120
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
15.212
Buy
MA10
15.340
Buy
MA20
15.204
Buy
MA50
15.042
Buy
MA100
14.360
Buy
MA200
14.180
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 11.03%, representing a quarter-over-quarter decrease of 88.87%. The largest institutional shareholder is Carl Icahn, holding a total of 3.50M shares, representing 0.99% of shares outstanding, with 0.53% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Bausch Health Companies Inc
310.45M
--
Icahn Associates Corporation
Star Investors
3.50M
--
Deutsche Bank Securities Inc.
3.41M
-2.57%
Alberta Investment Management Corporation
3.27M
+8.58%
D. E. Shaw & Co., L.P.
2.61M
+38.79%
GoldenTree Asset Management, LP
2.58M
+14.90%
Oaktree Capital Management, L.P.
Star Investors
2.52M
--
Glenview Capital Management, LLC
Star Investors
1.55M
+210.77%
Whitebox Advisors, L.L.C.
1.29M
-20.41%
Nomura Securities Co., Ltd.
1.26M
--
1
2

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 7.24, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.63. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
7.24
Change
0
Beta vs S&P 500 index
0.63
VaR
--
240-Day Maximum Drawdown
+47.22%
240-Day Volatility
+47.27%

Return

Best Daily Return
60 days
+5.00%
120 days
+5.25%
5 years
--
Worst Daily Return
60 days
-4.26%
120 days
-6.42%
5 years
--
Sharpe Ratio
60 days
+1.47
120 days
+1.70
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+47.22%
3 years
+48.07%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.51
3 years
+0.02
5 years
--
Skewness
240 days
-0.81
3 years
+0.15
5 years
--

Volatility

Realised Volatility
240 days
+47.27%
5 years
--
Standardised True Range
240 days
+3.43%
5 years
--
Downside Risk-Adjusted Return
120 days
+279.77%
240 days
+279.77%
Maximum Daily Upside Volatility
60 days
+23.55%
Maximum Daily Downside Volatility
60 days
+20.45%

Liquidity

Average Turnover Rate
60 days
+0.22%
120 days
+0.23%
5 years
--
Turnover Deviation
20 days
+8.03%
60 days
+26.09%
120 days
+31.29%

Peer Comparison

Healthcare Equipment & Supplies
Bausch + Lomb Corp
Bausch + Lomb Corp
BLCO
6.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc
ZBH
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI